Novo Nordisk Stock Slides 8% After 2030 Strategy; CEO Signals M&A as CagriSema Data Lands

Novo Nordisk (NYSE: NVO) shares suffered their sharpest decline in months after the drugmaker’s long-term strategy failed to ease concerns about slowing growth, pricing pressure, and its reliance on semaglutide, even as fresh Phase 3 data gave investors a more favorable look at next-generation obesity candidate CagriSema. Novo’s U. S.

-listed shares closed 7. 96% lower at $39. 80 on Monday, Sept.

Visit Website